Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts

• Váldodahkkit: Kirill Gorshkov (Dahkki), Amy Q. Wang (Dahkki), Wei Sun (Dahkki), Ethan Fisher (Dahkki), Marta Frigeni (Dahkki), Marc Singleton (Dahkki), Natasha Thorne (Dahkki), Bradley Class (Dahkki), Wenwei Huang (Dahkki), Nicola Longo (Dahkki), Minh‐Ha T. Do (Dahkki), Elizabeth A. Ottinger (Dahkki), Xin Xu (Dahkki), Wei Zheng (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2019-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Creatine transporter deficiency (CTD) is a metabolic disorder resulting in cognitive, motor, and behavioral deficits. Cyclocreatine (cCr), a creatine analog, has been explored as a therapeutic strategy for the treatment of CTD. We developed a rapid, selective, and accurate HILIC ultra‐perfo...